54
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          MRE11 within the MRE11-RAD50-NBS1 (MRN) complex acts in DNA double-strand break repair (DSBR), detection, and signaling; yet, how its endo- and exonuclease activities regulate DSBR by nonhomologous end-joining (NHEJ) versus homologous recombination (HR) remains enigmatic. Here, we employed structure-based design with a focused chemical library to discover specific MRE11 endo- or exonuclease inhibitors. With these inhibitors, we examined repair pathway choice at DSBs generated in G2 following radiation exposure. While nuclease inhibition impairs radiation-induced replication protein A (RPA) chromatin binding, suggesting diminished resection, the inhibitors surprisingly direct different repair outcomes. Endonuclease inhibition promotes NHEJ in lieu of HR, while exonuclease inhibition confers a repair defect. Collectively, the results describe nuclease-specific MRE11 inhibitors, define distinct nuclease roles in DSB repair, and support a mechanism whereby MRE11 endonuclease initiates resection, thereby licensing HR followed by MRE11 exonuclease and EXO1/BLM bidirectional resection toward and away from the DNA end, which commits to HR.

          Related collections

          Author and article information

          Journal
          Mol Cell
          Molecular cell
          Elsevier BV
          1097-4164
          1097-2765
          Jan 09 2014
          : 53
          : 1
          Affiliations
          [1 ] Genome Damage and Stability Centre, University of Sussex, Brighton BN1 9RQ, UK; Advanced Scientific Research Leaders Development Unit, Gunma University, Maebashi, Gunma 371-8511, Japan.
          [2 ] Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; The Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
          [3 ] Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; The Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA; The School of Biotechnology, Amrita University, Kollam, Kerala 690525, India.
          [4 ] Departments of Radiation Oncology and Medical Biophysics, University of Toronto, ON M5G 2M9, Canada.
          [5 ] Genome Stability Laboratory, Laval University Cancer Research Center, Hôtel-Dieu de Québec, 9 McMahon, QC G1R 2J6, Canada.
          [6 ] Department of Radiation Oncology, Department of Genetics, Erasmus University Medical Center, P.O. Box 2040, Rotterdam 3000 CA, the Netherlands.
          [7 ] Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy.
          [8 ] Genome Damage and Stability Centre, University of Sussex, Brighton BN1 9RQ, UK.
          [9 ] Genome Damage and Stability Centre, University of Sussex, Brighton BN1 9RQ, UK. Electronic address: p.a.jeggo@sussex.ac.uk.
          [10 ] Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; The Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA. Electronic address: jatainer@lbl.gov.
          Article
          S1097-2765(13)00828-9 NIHMS546540
          10.1016/j.molcel.2013.11.003
          3909494
          24316220
          d21474fd-3890-40b3-907a-9f167e9ebdce
          Copyright © 2014 Elsevier Inc. All rights reserved.
          History

          Comments

          Comment on this article